However, according to a new study, help may soon be at hand.
Secondly, these viruses evolve rapidly - so even if we could produce vaccines to cover the full spectrum of rhinoviruses, they would quickly become resistant.
An experimental drug used in laboratory tests stopped rhinovirus using a human protein to build its protective shell, or capsid, exposing its genetic heart and preventing it from replicating.
The molecule was initially discovered when searching for a way to take on malaria parasites. They found two compounds that seemed to work well together, so they combined them to make IMP-1088.
"The common cold is an inconvenience for most of us, but can cause serious complications in people with conditions like asthma and COPD", said lead researcher Ed Tate, a professor of chemistry at Imperial College, in the statement. NMT is vital for the survival of cold viruses; without it, they can not replicate and spread.
The treatment blocks a key protein in the body's cells that cold viruses normally hijack to self-replicate and spread. The team's findings were recently published in the journal Nature Chemistry.
The new treatment developed at London's Imperial College blocks the protein, cutting off the infection at an early stage. The early tests also suggest that the drug causes no harm to host cells.
This new molecule, however, completely blocked several strains of the virus without affecting human cells, but further studies are needed to make sure it is not in any way toxic to humans. Additionally, the molecule also works against viruses related to the cold virus, such as polio and foot and mouth disease viruses.
Though other drugs that target human cells in this way have been trialed before, IMP-1088 is "more than 100 times more potent" than its predecessors.
Another concern is outlined by Prof.
Previous efforts to create drugs that target human cells rather than infections have failed thanks to "toxic side effects". Millions of people every year also receive unnecessary antibiotic prescriptions from doctors for the common cold making it a major source of our growing antibiotic resistance problem.